Comparison · NCT00272779-sae
ATV/RTV/Tenofovir/Emtricitabine vs LPV/RTV/Tenofovir/Emtricitabine: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. ATV/RTV/Tenofovir/Emtricitabine vs LPV/RTV/Tenofovir/Emtricitabine: serious adverse events. Trial comparisons, record NCT00272779-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00272779-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.138 | 0.109 | 0.174 | wilson | |
| Risk in group 2 | 0.11 | 0.0839 | 0.143 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0285 | -0.0154 | 0.0724 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.26 | 0.884 | 1.79 | log | |
| Odds ratio, group 1 over group 2 | 1.3 | 0.869 | 1.95 | log | |
| Number needed to harm, for one more participant with a serious adverse event on ATV/RTV/Tenofovir/Emtricitabine than on LPV/RTV/Tenofovir/Emtricitabine | 35.1 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | ATV/RTV/Tenofovir/Emtricitabine | Participants were administered an oral dose of Atazanavir (ATV) 300 mg and ritonavir (RTV) 100 mg once daily along with food. Doses were taken 24 hours apart at the same time as fixed dose combination tenofovir (TDF) 300 mg plus emtricitabine (FTC) 200 mg once daily. | 61 | 441 | EG000 |
| Group 2 | LPV/RTV/Tenofovir/Emtricitabine | Participants were administered lopinavir (LPV) 400 mg or ritonavir (RTV) 100 mg twice daily along with food. Doses were taken approximately 12 hours apart while tenofovir (TDF) 300 mg once daily and emtricitabine (FTC) 200 mg once daily was administered at the same time as 1 of the 2 daily doses of LPV/RTV. | 48 | 437 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
Source ClinicalTrials.gov
Trial
- Title
- BMS-Reyataz Study in Treatment in Naive Subjects to Compare the Efficacy and Safety Between Boosted Reyataz and Kaletra When in Combination With Fixed Dose Truvada
- NCT number
- NCT00272779
- Phases
- PHASE3
- Conditions
- HIV Infections
- Interventions
- ATV, RTV, Tenofovi-Emtricitabine (TDF/FTC) tablet, LPV
- Lead sponsor
- Bristol-Myers Squibb
- Results first posted
- 2011-05-09
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00272779?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00272779-sae